Literature DB >> 7905341

Characterization of somatostatin receptors in guinea-pig isolated ileum, vas deferens and right atrium.

W Feniuk1, J Dimech, P P Humphrey.   

Abstract

1. Somatostatin14 (SS14) inhibits neurogenically mediated contractile responses in guinea-pig ileum and vas deferens and exerts a direct negative inotropic action in guinea-pig spontaneously beating right atrium. In this study, the receptors mediating these inhibitory effects have been characterized by comparing the potencies of several cyclic somatostatin analogues. 2. In the guinea-pig ileum, SS14, somatostatin28 (SS28), somatostatin25 (SS25) and several smaller cyclic somatostatin analogues including octreotide, angiopeptin and CGP 23996, inhibited neurogenically mediated contractile responses, each being of similar potency. 3. In contrast, in the guinea-pig vas deferens and right atrium, SS28 was about 30 times more potent than SS14. However, although angiopeptin was nearly as potent as SS14 as an agonist in the vas deferens, in guinea-pig atrium angiopeptin had low intrinsic activity and antagonized the negative inotropic action of both SS14 and SS28 (pKB values of 7.4 and 7.2, respectively). CGP 23996 was 2-7 times weaker than SS14 in guinea-pig vas deferens and atria. 4. Phosphoramidon (1 microM) and amastatin (10 microM) did not influence the potency of SS14 or SS28 in either the guinea-pig ileum or right atrium. In the guinea-pig vas deferens, phosphoramidon and amastatin did not affect the potency of SS28, but enhanced the potency of SS14 about 5 fold. Despite the presence of phosphoramidon and amastatin, SS28 was still more potent than SS14 in the vas deferens. 5. The putative somatostatin receptor blocking drug, cyclo(7-aminoheptanoyl Phe-D-Trp-Lys-Thr[Brl]) (CPP; 1 microM), did not antagonize the effects of either SS14 or SS28 in ileum, vas deferens or atrial preparations. 6. Somatostatin14 did not modify the contractile action of carbachol or alpha,beta-methylene ATP in the ileum and vas deferens respectively, suggesting that the site of the inhibitory effects on neurogenically mediated contractile responses in both preparations was pre-junctional. Consistent with this conclusion was the observation that the inhibitory effect of SS14 was markedly and inversely related to the external Ca2+concentration. The inhibitory effect of SS14 in guinea-pig atrium was only partly dependent on the external Ca2+ concentration.7. The somatostatin receptors mediating the inhibitory effect of SS14 in the ileum and vas deferens can be distinguished by the differential relative potencies of SS14 and SS28. In the former, SS14 and SS28 have similar potency whilst in the latter SS28 is much more potent. In this respect, the somatostatin receptor mediating negative inotropy in the guinea-pig right atrium appears similar to that identified in the vas deferens.8. We suggest that the somatostatin receptor mediating inhibition of neurogenic contraction in the ileum is similar to the recently cloned SSTR2 receptor. In contrast, the somatostatin receptor mediating negative inotropy in the atrium and inhibition of neurotransmission in the vas deferens appears similar to the SSTR4 receptor which recognises SS28 with higher affinity than SS14.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7905341      PMCID: PMC2175805          DOI: 10.1111/j.1476-5381.1993.tb13935.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  Somatostatin inhibits adrenergic and cholinergic neurotransmission in smooth muscle.

Authors:  M L Cohen; E Rosing; K S Wiley; I H Slater
Journal:  Life Sci       Date:  1978-10-23       Impact factor: 5.037

2.  Somatostatin and ACTH are peptides with partial antagonist-like selectivity for opiate receptors.

Authors:  L Terenius
Journal:  Eur J Pharmacol       Date:  1976-07       Impact factor: 4.432

3.  The inhibitory effect of somatostatin peptides on the rat anococcygeus muscle in vitro.

Authors:  T Priestley; G N Woodruff
Journal:  Br J Pharmacol       Date:  1988-05       Impact factor: 8.739

4.  Analogs of somatostatin selectively label distinct subtypes of somatostatin receptors in rat brain.

Authors:  K Raynor; T Reisine
Journal:  J Pharmacol Exp Ther       Date:  1989-11       Impact factor: 4.030

5.  Putative mechanisms involved in excitatory and inhibitory effects of somatostatin on intestinal motility.

Authors:  T Takeda; K Taniyama; S Baba; C Tanaka
Journal:  Am J Physiol       Date:  1989-10

6.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

7.  Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone.

Authors:  P Brazeau; W Vale; R Burgus; N Ling; M Butcher; J Rivier; R Guillemin
Journal:  Science       Date:  1973-01-05       Impact factor: 47.728

8.  Evidence that somatostatin enhances endogenous acetylcholine release in the rat hippocampus.

Authors:  D M Araujo; P A Lapchak; B Collier; R Quirion
Journal:  J Neurochem       Date:  1990-11       Impact factor: 5.372

9.  Somatostatin decreases the calcium inward current in guinea-pig atria.

Authors:  T Ohmura; M Nishio; S Kigoshi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

10.  An analysis of the negative inotropic action of somatostatin.

Authors:  R Quirion; D Regoli; F Rioux; S St-Pierre
Journal:  Br J Pharmacol       Date:  1979-06       Impact factor: 8.739

View more
  8 in total

Review 1.  Somatostatin.

Authors:  T Reisine
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

2.  Somatostatin sst2 receptor-mediated inhibition of parietal cell function in rat isolated gastric mucosa.

Authors:  M A Wyatt; E Jarvie; W Feniuk; P P Humphrey
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 3.  Molecular pharmacology of somatostatin receptors.

Authors:  D Hoyer; H Lübbert; C Bruns
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000

4.  Localization and pharmacological characterization of somatostatin sst2 sites in the rat cerebellum.

Authors:  C Piwko; V S Thoss; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

Review 5.  Drug design at peptide receptors: somatostatin receptor ligands.

Authors:  Jason P Hannon; Caroline Nunn; Barbara Stolz; Christians Bruns; Gisbert Weckbecker; Ian Lewis; Thomas Troxler; Konstanze Hurth; Daniel Hoyer
Journal:  J Mol Neurosci       Date:  2002 Feb-Apr       Impact factor: 3.444

6.  Further evidence from functional studies for somatostatin receptor heterogeneity in guinea-pig isolated ileum, vas deferens and right atrium.

Authors:  W Feniuk; J Dimech; E M Jarvie; P P Humphrey
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

7.  Mediation by SRIF1 receptors of the contractile action of somatostatin in rat isolated distal colon; studies using some novel SRIF analogues.

Authors:  E S McKeen; W Feniuk; P P Humphrey
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

8.  Somatostatin receptors mediating inhibition of basal and stimulated electrogenic ion transport in rat isolated distal colonic mucosa.

Authors:  E S McKeen; W Feniuk; P P Humphrey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-10       Impact factor: 3.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.